Investor Presentaiton

LSI Segment Highlights - 9M'FY20 Revenue Particulars¹ Specialty Intermediates Nutritional Products Life Science Chemicals Reported EBITDA Adjusted EBITDA Reported EBITDA Margin (%) Adjusted EBITDA Margin (%) LSI revenue at Rs 2,356 Crore, decrease of 11% YoY Specialty Intermediates 9M'FY19 9M'FY20 % Change ☐ 2,633 2,356 (11%) 683 831 22% 302 373 24% 1,648 1,151 (30%) 344 313 (9%) 344 321 (7%) 13.1% 13.3% 13.1% 13.6% Revenue Breakup by End-Use Industries 28% 27% 24% 22% 16% 13% 1% 1% 36% 33% Revenue increase of 22% YoY led by strong demand and better prices in key products such as Pyridine, Beta and Pyridine derivatives Positive traction for pyridine derivatives launched in last one year Nutritional Products • Revenue increase of 24% YoY led by better prices of Vitamin B3 Demand scenario is expected to be strong in Q4 FY'20 Life Science Chemicals ☐ Pharma Agro Nutrition Personal Specialty Care Chemicals • 9M'FY19 9M'FY20 1,758 1,429 Geography Wise Revenue¹ ☐ Revenue decreased 30% YoY due to significant drop in Acetic Acid price, which led to price correction of Life sciences chemicals products. EBITDA at Rs 313 Crore decreased by 9% YoY with margin of 13.3% as compared to 13.1% in 9M'FY19. Strong growth in profitability in Specialty Intermediates and Nutritional Products businesses LSC profitability impacted due to significantly higher molasses prices and lower contribution in acetyl business due to subdued demand in export market Adjusted EBITDA at Rs 321 Crore, with a margin of 13.6% as compared to 13.1% in 9M'FY19 481 467 264 320 129 139 India North America Europe & ROW Japan 9M'FY19 ■9M'FY20 1. All figures are in Rs Crore unless otherwise stated JUBILANT LIFESCIENCES

View entire presentation